Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

Keyphrases

• Adult Participants 50%
• Adverse Events 25%
• African American 25%
• All-cause Mortality 25%
• Antibody Treatment 100%
• Area under the Curve 25%
• Bamlanivimab 50%
• Black African 25%
• COVID-19 25%
• COVID-19 Related 50%
• Drug Exposure 25%
• Efficacy Data 25%
• Etesevimab 50%
• Hispanic or Latino 25%
• Hospitalization 50%
• Moderate COVID-19 25%
• Monoclonal Antibody 50%
• Pediatric 100%
• Pediatric Population 25%
• Pharmacokinetics 100%
• Placebo-controlled 100%
• Randomized Phase II Trial 100%
• Risk Factors 25%
• Safety Data 25%
• SARS-CoV-2 Antibodies 100%
• Serious Adverse Events 25%
• Severe COVID-19 25%
• Severe Disease 25%
• Trial Registration 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 66%
• All Cause Mortality 33%
• Disease 33%
• Monoclonal Antibody 66%
• Pharmacokinetics 100%
• Placebo 100%
• SARS Coronavirus 100%